This website uses cookies to ensure you get the best experience on our website.
Privacy Policy
I Agree
REVIEW UroToday
Contact
Login
Sign Up Free
Transformative Evidence
mCRPC
PROfound Trial
The RALU Study: Treatment Considerations in the First Line Setting of mCRPC
VISION Trial
mHSPC
ARANOTE Trial
ARASENS Trial
nmCRPC
ARAMIS Trial
nmCSPC
EMBARK Trial
PSMA PET Imaging
COBRA Trial
CONDOR Trial
OSPREY Trial
Bladder Cancer
Bladder Cancer Detection
CORE-001 Study
ADSTILADRIN
Centers of Excellence
Urologic Oncology
Left Group
Health Policy
Health Policy
Ruchika Talwar, MD
Bladder Cancer
Bladder Cancer
Ashish Kamat, MD
Advanced Bladder Cancer
Shilpa Gupta, MD
Trimodality Therapy
Leslie Ballas, MD
Kidney Cancer
Advanced Kidney Cancer
Pedro Barata, MD, MSc
Endourology
Endourology
Jaime Landman, MD
Prostate Cancer
Localized Prostate Cancer
Matthew R. Cooperberg, MD, MPH
Decipher Genomic Classifier
Imaging Center
Phillip Koo, MD
mHSPC
Neeraj Agarwal, FASCO, MD
nmCRPC
Zachary Klaassen, MD, MSc
mCRPC Treatment
A. Oliver Sartor, MD
PSMA-Targeted Therapy
Advanced Prostate Cancer
Zachary Klaassen, MD, MSc
Disparities: Social Determinants of Health
Disparities: Social Determinants of Health
Samuel L. Washington III, MD, MAS
Translational Prostate Cancer
Translational Science in Prostate Cancer
Andrea Miyahira, Ph.D
Women in Science
Andrea Miyahira, Ph.D
Upper Tract Urothelial Carcinoma
Upper Tract Urothelial Carcinoma
Sam S. Chang, MD, MBA
TESTICULAR, PENILE & RARE GU MALIGNANCIES
Testicular Cancer
Pelvic Health & Reconstruction
Bladder Health
Diane K. Newman, DNP, ANP-BC, FAAN
Pelvic Health
Diane K. Newman, DNP, ANP-BC, FAAN
Society of Urodynamics, Female Pelvic Medicine & Urogenital Reconstruction (SUFU)
Stephen R. Kraus, MD
Urologic Catheters (Includes CAUTI)
Diane K. Newman, DNP, ANP-BC, FAAN
Videos
Exclusives
Conferences
Exclusive Collaborations
Independent Medical Education
Covid-19
The Prostate Cancer Foundation
Health Policy in Urological Diseases
Disparities: Social Determinants of Health
Practice Guidelines Reviews
Urologic Oncology
Prostate Cancer
Bladder Cancer
Kidney Cancer
Upper Tract Urothelial Tumors
Testicular Cancer
Endourology
Pelvic Health & Reconstruction
Pelvic Health & Reconstruction
Trials in Progress
Trials in Progress
Bladder Cancer
IMMORTAL
PIVOT-006
Kidney Cancer
RadiCal
SAMURAI
Middle Side
Prostate Cancer
ARAMON
ARASEC
ARASTEP
CLARIFY
ECLIPSE
ESCAPE
FORT
Right Side
Prostate Cancer
Masofaniten (EPI-7386)
METANOVA
NRG-GU 0101
PROMISE
RTIRE
SECuRE
SHORTER
Clinical Trials
From the Editor
Search Clinical Trials
Articles
Urology (benign and malignant)
Urologic Oncology
Men's Health
Endourology & Stones
Pediatric Urology
COVID-19 and Genitourinary Cancers
Pelvic Health
Pelvic Health & Reconstruction
Conference Coverage
Recent Conferences
SCS AUA 2024
ASTRO 2024
IBCN 2024
ESMO 2024
BCAN TT 2024
All Conferences
View All
Quick Takes
ESMO 2024
PCF
UroToday Home
Conference Highlights
ASCO GU 2016
ASCO GU 2016
Prostate Cancer
mCRPC Treatment
Bladder Cancer
Renal Cancer
Penile & Urethral Cancers
Testicular Cancer
ASCO GU 2016 Prostate Cancer
Viewing 1-20 of 37 articles
ASCO GU 2016 Phase II clinical study of radium-223 chloride (BAY 88-8223) in Japanese patients with symptomatic castration-resistant prostate cancer (CRPC) with bone metastases. - Session Highlights
ASCO GU 2016 Bladder and Bowel Symptoms with Intensity-Modulated Radiation Therapy (IMRT) for Prostate Cancer - Poster
ASCO GU 2016 More CNS Events With Enzalutamide Vs. Bicalutamide Treatment of mCRPC - Session Highlights
ASCO GU 2016 Large Study Reveals Significant Glucocorticoid Use in Both Treated and Untreated Prostate Cancer Patients - Session Highlights (Updated)
In 2016, What is Progress in the Treatment of Hormone-Naïve Prostate Cancer?
ASCO GU 2016 Cardiovascular events in prostate cancer patients: A comparative analysis of German claims data. - Session Highlights
ASCO GU 2016 Biology of Bone Metastases - Session Highlights
ASCO GU 2016 Is NaF PET Ready to Replace Technetium for Clinical Care and Research? - Session Highlights
ASCO GU 2016 Integrative Clinical Genomics in Castration-Resistant Prostate Cancer - Session Highlights
ASCO GU 2016 The Incidence and Distribution of Lymph Node Metastases in Localized Prostate Cancer: Role of Imaging and Surgery - Session Highlights
ASCO GU 2016 Molecular Risk Stratification in Localized Prostate Cancer: Current Status and Unanswered Questions - Session Highlights
ASCO GU 2016 Ra-223 Retreatment Succeeds in mCRPC - Session Highlights
ASCO GU 2016 New Combined Clinical Risk (CCR) Score Aids in Active Surveillance Decision-making in Prostate Cancer - Session Highlights
ASCO GU 2016 Active Surveillance: How to Measure, Manage, and Improve. - Poster Session Highlights
ASCO GU 2016 Urologists’ experiences with treatment of castration-resistant prostate cancer. - Poster Session Highlights
ASCO GU 2016 After the 2012 USPSTF Recommendation on Prostate Cancer Screening, Higher Gleason Grades and More Positive Cores
ASCO GU 2016 Management of metastatic prostate cancer patients in first line: Audit of real-life practices - Poster Session Highlights
ASCO GU 2016 Best of Journals: Prostate Cancer Medical Oncology - Session Highlights
ASCO GU 2016 Best of Journals: Prostate Cancer Surgical Oncology - Session Highlights
ASCO GU 2016 Best of Journals: Prostate Cancer Radiation Oncology - Session Highlights
1
2
×
Login
Login to update email address, newsletter preferences and use bookmarks.
Email
Password
Login
Forgot Password?
Sign Up Free